Document Type
Journal Article
Publication Date
3-27-2017
Journal
Current HIV/AIDS Reports
Volume
14
Issue
2
Inclusive Pages
54-62
DOI
10.1007/s11904-017-0352-1
Abstract
Purpose of Review
The purpose of this study is to summarize recent advances in the use of broadly neutralizing antibodies (bNAbs) as therapeutics in human clinical trials and in non-human primate (NHP) models. We seek to highlight lessons from these studies with an emphasis on consequences to the virus and immune system.
Recent Findings
In the past 10 years, advances in HIV-1 trimer structure and B cell isolation methods have precipitated the identification of “new-generation” anti-HIV antibodies with broad and potent neutralization. In the past 2 years, the concept of using these bNAbs as therapeutic tools has moved from NHP models into human clinical trials. These trials have investigated the effects of bNAb infusions into patients chronically infected with HIV-1, while the NHP model has investigated treatment during acute infection.
Summary
Through this work, the relationship between in vitro breadth and potency and in vivo clinical effect, although unresolved, is gradually being elucidated. These results emphasize the need for combination antibody therapy.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
APA Citation
Bhiman, J., & Lynch, R. (2017). Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System.. Current HIV/AIDS Reports, 14 (2). http://dx.doi.org/10.1007/s11904-017-0352-1
Peer Reviewed
1
Open Access
1
Comments
Reproduced with permission of Springer International Publishing AG. Current HIV/AIDS Reports.